Table 2.
Multivariable analysis of all-cause mortality, locoregional recurrence, and distant metastasis for patients receiving neoadjuvant chemotherapy and total mastectomy
| All-Cause Mortality | LRR | DM | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||
| Response of AJCC-stages ratio | Equal-stages | ref | < 0.0001 | ref | < 0.0001 | ref | < 0.0001 |
| pCR | 0.21 (0.13-0.34) | 0.19 (0.08-0.48) | 0.33 (0.23-0.47) | ||||
| Downstages | 0.56 (0.48-0.65) | 0.67 (0.51-0.89) | 0.61 (0.52-0.70) | ||||
| Upstages | 1.85 (1.56-2.18) | 1.17 (0.84-1.62) | 1.61 (1.36-1.90) | ||||
| AJCC stage | IIB | ref | < 0.0001 | ref | 0.0017 | ref | < 0.0001 |
| IIIA | 1.85 (1.54-2.22) | 1.15 (1.03-1.59) | 1.61 (1.36-1.92) | ||||
| IIIB | 2.66 (2.21-3.21) | 1.60 (1.15-2.22) | 2.24 (1.88-2.67) | ||||
| IIIC | 3.76 (2.97-4.77) | 2.06 (1.34-3.16) | 2.91 (2.31-3.66) | ||||
| Age | 20-49 | ref | 0.9544 | ref | 0.2095 | ref | 0.1458 |
| 50+ | 1.00 (0.88-1.15) | 1.02 (0.86-1.09) | 1.07 (0.76-1.10) | ||||
| Diagnosis year | 2007-2010 | ref | 0.7865 | ref | 0.4417 | ref | 0.3807 |
| 2011-2015 | 0.98 (0.86-1.13) | 0.90 (0.70-1.17) | 1.06 (0.93-1.21) | ||||
| CCI scores | 0 | ref | < 0.0001 | ref | 0.1208 | ref | 0.3412 |
| 1 | 0.89 (0.73-1.10) | 1.05 (0.72-1.53) | 1.08 (0.89-1.31) | ||||
| 2+ | 1.69 (1.34-2.14) | 1.03 (0.99-1.18) | 1.20 (0.92-1.57) | ||||
| Differentiation | III | ref | < 0.0001 | ref | 0.4035 | ref | 0.0418 |
| II | 0.76 (0.66-0.88) | 0.96 (0.81-1.13) | 0.94 (0.81-1.09) | ||||
| I | 0.42 (0.28-0.62) | 0.80 (0.64-1.29) | 0.63 (0.45-0.89) | ||||
| NACT regimen | Anthracycline | ref | 0.4389 | ref | 0.6519 | ref | 0.1084 |
| Taxanes | 1.07 (0.91-1.26) | 0.91 (0.67-1.24) | 1.09 (0.91-1.52) | ||||
| Both | 1.07 (0.91-1.26) | 1.11 (0.82-1.49) | 1.16 (0.99-1.37) | ||||
| Neither | 1.24 (0.95-1.63) | 1.01 (0.60-1.71) | 1.26 (0.93-1.79) | ||||
| Nodal surgery | ALND | ref | 0.8862 | ref | 0.1204 | ref | 0.4326 |
| SLNB | 0.93 (0.61-1.42) | 0.92 (0.24-1.09) | 0.79 (0.54-1.16) | ||||
| Adjuvant PMRT | 0.75 (0.65-0.87) | 0.0001 | 0.43 (0.37-0.49) | < 0.0001 | 0.84 (0.64-1.10) | 0.1991 | |
| Hormone receptor positive | 0.68 (0.59-0.77) | < 0.0001 | 1.15 (0.89-1.49) | 0.2737 | 0.95 (0.80-1.31) | 0.2451 | |
| HER2 positive | 0.99 (0.87-1.13) | 0.9283 | 1.92 (1.51-2.45) | < 0.0001 | 1.51 (1.33-1.72) | < 0.0001 | |
| Academic hospital | Yes | ref | 0.2981 | ref | 0.2759 | ref | 0.3640 |
| No | 0.93 (0.82-1.06) | 0.87 (0.68-1.12) | 1.06 (0.93-1.21) | ||||
HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; NACT, neoadjuvant chemotherapy; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; LRR, locoregional recurrence; DM, distant metastasis.